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Purpose: Tumors of the small bowel are rare, accounting for about 3-6% of all gastrointestinal neoplasms, though they cover 
more than 90% of the intestinal surface. However, diagnosis and treatment are difficult and present an ongoing challenge 
for both gastrointestinal surgeons and gastroenterologists. The aim of this study was to investigate the clinical features of 
small bowel tumors.
Methods: Between November 1994 and November 2007, 81 patients underwent treatments for primary tumors in the je-
juno-ileal region at the Department of Surgery, Kangnam St. Mary’s Hospital, the Catholic University of Korea. A retro-
spective review of the patients’ characteristics and variable tumor factors was performed. 
Results: The mean age of the patients was 53.2 years with 48 men and 33 women. The most common symptom was abdom-
inal pain (59.3%), followed by bleeding (22.2%) and an abdominal mass (6.2%). We found that the patients with ileal tumors 
complained mainly of abdominal pain (72.9%) whereas the patients with jejunal tumors presented with gastrointestinal 
bleeding (36.4%) (P = 0.048). Seventy-six of the 81 patients (93.8%) had malignant tumors, including 40 (49.4%) gastroin-
testinal stromal tumors, 26 (32.1%) lymphomas and 5 (6.2%) adenocarcinomas. No postoperative mortalities were ob-
served. The overall 5-year survival rate of the patients with malignant small bowel tumors was 31.8%.
Conclusion: Because the clinical features of a primary tumor of the small bowel are obscure and its diagnosis is difficult, 
maintaining a high degree of suspicion and recognizing the possibility of a primary small bowel tumor are important. 
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Since small intestine tumors have a different prognosis and 
since the appropriate surgical and medical treatments are based 
on their histological diagnosis, selection of treatment methods 
through an accurate diagnosis is important [3]. Even though 
cases with an abdominal mass, hemorrhage, or peritonitis 
caused by an intestinal perforation can be easily diagnosed by 
clinical presentation, physical examination, and imaging stud-
ies, the diagnosis for tumors of the small intestine is usually 
difficult because most of them have nonspecific clinical symp-
toms and nonspecific physical examination results compared 
to other tumors. In addition, because of the anatomical loca-
tion of the small intestine, excluding the proximal duodenal 
area, a direct approach is difficult; thus, in spite of the devel-
opment of diagnostic techniques, the diagnosis rate is not high 
[4]. Therefore, when such a tumor is diagnosed, it is usually 
accompanied by complications or is far advanced, showing a 
poor prognosis [5].Therefore, in this study, we analyzed the 
clinical characteristics of and the treatment methods, and prog-
noses for patients with primary small bowel tumors and tried 
to find differences based on clinical presentations, physical 
examination results, and histological findings. 
INTRODUCTION
The small intestine represents 90% of the entire surface of the 
gastrointestinal tract, and 75% of its length. However, tumors 
rarely develop in the small intestine, showing an incidence of 
5% forf all tumors in the gastrointestinal tract, and among 
them, malignant tumors represent only 1-2% of the total [1]. 
Histologically, of the small intestine tumors, more than 60% 
are malignant tumors, and among them, the incidences of gas-
trointestinal interstitial tumors, adenocarcinomas, malignant 
lymphomas, and carcinoids have been reported to be high [2]. 
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METHODS
Eighty one patients were treated for primary small bowel tu-
mors in the Department of Surgery, Seoul Saint Mary’s Hos-
pital, the Catholic University of Korea, from November 1994 
to November 2007. Age, gender, primary tumor site, clinical 
symptoms and signs, surgery methods, prognosis, histological 
findings, and other clinical results were retrospectively compared 
and analyzed. Primary small bowel tumors were considered, 
tumors that developed in the duodenum were excluded, and 
only tumors that developed in the jejunum and the ileum were 
analyzed. In regard to the gastrointestinal stromal tunor (GIST), 
according to the AJCC classification, Stage I cases were con-
sidered as benign, and cases higher than Stage II were classi-
fied as having malignant potentials. Most patients were admit-
ted to the hospital with abdominal symptoms. Diagnostic pre-
operative studies included CT, MRI, PET-CT and endoscopy. 
Eleven non-diagnosed patients underwent a diagnostic lapa-
rotomy. 
For statistical analysis, the chi-square test was used for cate-
gorical variables. The survival rate was analyzed by using the 
Kaplan-Meier method. P values less than 0.05 were considered 
to be significant. 
RESULTS
Gender and age
Among the 81 patients, 48 were male and 33 were female, males 
being more prevalent. The mean age was 53.2 years (range, 2 
to 84 years), and 38 patients (46.9%) were in the 5th decade, 
which showed the highest frequency.
Pathohistological findings and the distribution of the 
primary tumor site
A review of the pathohistological findings of small bowel tu-
mors showed that, among the 81 cases, 25.9% were benign, 
and 74.1% were malignant. Their pathological classifications 
are shown in Table 1. Among the 81 cases, primary tumors in 
the jejunum were observed in 33 cases (40.7%), and tumors 
were onserved in the ileum in 48 cases (59.3%). An examina-
tion of the correlation of primary tumor site with histological 
diagnostic distribution showed that the gastrointestinal stro-
mal tumors were found preferentially in the jejunum (75.8%) 
and that malignant lymphomas were found preferentially in 
the ileum (50%) (P = 0.001). 
Clinical symptoms and physical examination findings 
The major symptoms of the patients at the time of admission 
were 48 cases of abdominal pain (59.3%), 18 cases of hemor-
rhage (22.2%), and 5 cases of abdominal mass (6.2%). In ad-
dition, 10 patients (12.3%) complained of constipation, vom-
iting, vertigo, and diarrhea. An examination of the correlation 
of the primary tumor site with the major symptoms of the pa-
tients showed that abdominal pain and hemorrhage had simi-
lar frequencies of occurrence (39.3% vs. 36.4%) in tumors that 
developed in the jejunum and that abdominal pain had the 
highest frequency of occurrence (72.9%) in tumors that de-
veloped in the ileum (P = 0.048) (Fig. 1). 
When the symptoms are related to histological classification, 
in gastrointestinal stromal tumors, abdominal pain was ob-
served in 14 cases and hemorrhage in 10 cases. Patients with 
a malignant lymphoma showed symptoms such as abdominal 
pain, abdominal mass, and fever, or they were asymptomatic. 
Among the patients with a malignant lymphoma, abdominal 
pain appeared in 19 cases, being the most prevalent. Among 
patients with abdominal pain as the chief complaint, intestinal 
perforation or intussusceptions, as diagnosed by using abdom-
inal computed tomography or explo-laparatomy, were observed 
in 3 cases and 6 cases, respectively.
Table 1. Histologic findings of tumors
Pathology  Number
Benign 
   Gastrointestinal stromal tumor
   Inflammatory fibroid tumor 
   Adenomyoma 
   Adenoma 
21
16
  3
  1
  1
Malignant 
   Gastrointestinal stromal tumor
   Lymphoma 
   Adenocarcinoma 
   Leiomyosarcoma 
   Carcinoid 
   Neuroendocrine tumor 
60
24
26
  5
  3
  1
  1
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Fig. 1. Main Symptoms of primary small bowel tumors are signifi-
cantly different between those in the jejunum and those in the ileum.Journal of The Korean Society of
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Preoperative diagnosis
For pre-surgical diagnosis, abdominal computed tomography, 
upper gastrointestinal imaging, abdominal ultrasonography, or 
endoscopic examination were used in most cases. Most small 
bowel tumors were diagnosed by using abdominal computed 
tomography (44 cases), endoscopic examination (11 cases), 
and abdominal ultrasonography (5 cases). For 11 cases which 
were not diagnosed by any tests, an explo-laparotomy was per-
formed.
Surgical methods
Among the 81 patients, a radical resection was performed in 
75 cases, a resection and anastomosis in 69 cases (85.1%) and 
a wedge resection in 6 cases (7.4%); a bypass or other resec-
tion was performed in 6 cases. 
Outcomes and prognosis
Examining the postsurgical outcome of our patients none died 
of postsurgical complications. Among 26 lymphoma patients, 
postoperative radiation therapy and chemotherapy were per-
formed on 22 patients, and chemotherapy was performed on 
1 carcinoid patient, 1 neuroendocrine tumor patient and 11 
gastrointestinal stromal tumor patients. 
The mean follow-up observation period of the 74 malignant 
tumor patients was 54.7 months, and the mean survival time 
and the 5-year survival rate were observed to be 109.43 ± 8.3 
months and 64.8%, respectively (Fig. 2). In the analysis of the 
survival rate according to histological diagnosis, the 5-year 
survival rate of patients with gastrointestinal stromal tumors 
(82.5%) was observed to be statistically significantly higher 
than that for patients with a carcinoid (40%) or with a malig-
nant lymphoma (46.4%) (P = 0.0007) (Fig. 3).
DISCUSSION
Primary small bowel tumor is a very rare disease. Although 
the small intestine represents of 90% of the entire gastrointes-
tinal surface and 75% of its length, tumors developing in the 
small intestine are 5% of all tumors developing in the gastroin-
testinal tract, and among them, malignant tumors are merely 
1-2% [1]. The cause of carcinogenesis is not clear. Nonetheless, 
the incidence of malignant tumors has been reported to be par-
ticularly low in the small intestine because of the rapid regen-
eration and proliferation of the small intestine mucosa, and 
this lowers the sensitivity to cancer cells. Unlike the large in-
testine, in the small intestine, the number of bacteria is small, 
and carcinogens due to bacterial metabolites are generated 
less. In addition, the rate of food transit in the small intestine 
is rapid, and the time of contact with carcinogens is short, ben-
zopyren hydroxylase, which neutralizes carcinogens, being abun-
dant in the small intestine. Lastly, lymph node tissues and the 
concentration of IgA are high in the ileum, which protects the 
small intestine from viruses and suppresses tumor cell growth 
[6-8].
The distensibility of the small intestine is good, and the con-
tent is liquid, so clinical symptoms of small bowel tumors are 
nonspecific and manifest slowly. Because of these characteris-
tics, unless severe symptoms are shown, most cases are difficult 
to diagnose, and the disease is advanced when diagnosed in 
many cases [1]. Although most small bowel tumors are asymp-
tomatic, malignant tumors are known to show more symptoms 
than benign tumors. Darling et al. [9] have reported that 75% 
of small bowel tumors are benign; however, 75% of the patients 
on whom surgery had been performed due to symptoms had 
malignant tumors. Naef et al. [10] have reported that the most 
Fig. 2. Overall survival in patients with malignant small bowel tumors.
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Fig. 3. Overall survivals according to the histology of the primary small 
bowel tumors are significantly different.
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frequent clinical symptoms are abdominal pain, anemia, weight 
loss, and hemorrhage. Catena et al. [4] reported the clinical 
features of small bowel tumors that manifested during emer-
gency conditions requiring surgery, and intestinal obstruction 
was pointed out to be the most common symptom. In addi-
tion, intestinal perforation and intestinal hemorrhage were 
reported. 
An analysis of the clinical symptoms according to histologi-
cal findings revealed that gastrointestinal stromal tumors show 
hemorrhage, carcinoids showed bowel obstruction, malignant 
lymphomas showed perforation, and adenocarcinomas showed 
perforation or bowel obstruction [11]. These symptoms are 
known to differ with the characteristics of the tumors. Gastro-
intestinal stromal tumors develop in the small bowel muscle 
layer and grow in the bowel submucosal layer. They may grow 
toward the lumen and compress it, or grow laterally, or grow 
as dumbbell shapes. Particularly, growth of the tumor toward 
the lumen causes necrosis and ulcers in the mucosal layer and 
impairs the blood supply to the small bowel mucosa, resulting 
in intestinal hemorrhage due to the necrosis in the mucosal 
membrane. 
According to a study reported by Choi et al. [12] gastrointes-
tinal stromal tumors occur preferentially in the jejunum, which 
has more abundant muscle layers than the ileum. Malignant 
lymphomas occur preferentially in the ileum because the lym-
phoid tissues called Peyer’s patch associated with the intestine 
are distributed most abundantly overn the entire small intes-
tine. The size of a malignant lymphoma is larger than 5 cm in 
most cases, and it may invade from the mucosa to the small 
bowel wall. Therefore, abdominal pain frequently develops, 
and intestinal perforation may occur in approximately 25% of 
the cases [13]. The causes of an adenocarcinoma can be diverse, 
such as genetic and environmental factors, but similar to stom-
ach cancer or colorectal cancer, contact with carcinogenic ma-
terials may be an important factor. Therefore, adenocarcino-
mas have been reported to occur most preferentially in the 
duodenum, which has frequent contact with carcinogenic ma-
terials, followed by the jejunum [14].  
An adenocarcinoma starts from a villous adenoma and pro-
gresses to malignancy due to several factors in some cases. In 
such cases, as the adenoma becomes larger, it may cause intes-
tinal obstruction, and in some cases, hemorrhage and perfo-
ration caused by mucosal necrosis may be shown [15]. In our 
study, similar to other studies, gastrointestinal stromal tumors 
were observed to develop preferentially in the jejunum, and 
malignant lymphomas were observed to develop preferentially 
in the ileum (P = 0.001). In addition, in the analysis of the cor-
relation of primary tumor site with major symptoms, tumors 
that developed in the jejunum showed hemorrhage most fre-
quently, and tumors that developed in the ileum showed ab-
dominal pain most frequently (P = 0.048). This implies a cor-
relation with histological distribution. While hemorrhage is 
the major symptom in the jejunum due to the high incidence 
of gastrointestinal stromal tumors, abdominal pain is mainly 
presented in the ileum due to the high incidence of malignant 
lymphomas.
Until now, the prognosis of malignant tumors in the small 
intestine has been known to be very poor. The major causes 
are nonspecific symptoms, delay of diagnosis due to the diffi-
culty of diagnosis, high possibility of local metastasis or dis-
tant metastasis at the time of diagnosis, and detection of peri-
toneal metastasis and distant metastasis, up to 70%, at the time 
of surgery [16]. Miles et al. [17] have reported the 5-year sur-
vival rate for all small bowel tumors to be 20-36. That of car-
cinoids was 73%, which showed the best prognosis that of leio-
myosarcomas was 29%, that of malignant lymphomas was 27%, 
and that of adenocarcinomas was 15%, which showed the worst 
prognosis. The prognosis of small bowel adenocarcinomas is 
poor because of abundant lymphoid tissues in the small bowel 
mucosa, resulting in frequent local lymph node metastasis and 
liver metastasis. The 5-year survival rate was reported to be 
approximately 15-30% [18]. Lee et al. [19] have reported that 
the 5-year survival rate for primary small bowel lymphomas 
reached 53%, and among patients who had been treated ap-
propriately, 49.2% were completely cured. 
Although numerous studies have been conducted on factors 
affecting the prognosis for gastrointestinal stromal tumors that 
develop in the small intestine, none of the factors has been es-
tablished clearly. Gastrointestinal stromal tumors have diverse 
characteristics from benign to highly malignant. Therefore, 
gastrointestinal stromal tumors are frequently referred to as 
Stromal Tumors of Uncertain Malignant Potential [20]. Gas-
trointestinal stromal tumors in the small intestine have been 
reported to show recurrence rates higher than 50%. Neverthe-
less, prognostic factors have not been established clearly, and 
whether the tumor is malignant or not can only be determined 
when local recurrence or metastasis occurs [21]. In our study, 
the 5-year survival rate for malignant tumors was 64.8%, and 
the 5-year survival rates for gastrointestinal stromal tumors, 
adenocarcinomas, and malignant lymphomas were 82.5%, 40%, 
and 46.4%, respectively, which were similar to other studies.
Although primary small bowel tumors are rare, such tumors 
represent a disease whose diagnosis may be delayed due to non-
specific symptoms. In our study, the symptoms of gastrointes-
tinal stromal tumors, adenocarcinomas and malignant lym-
phomas occurring in the jejunum and the ileum differ accord-
ing to the clinical characteristics, the location of the tumor, 
and the histological classification of the tumor. Therefore, in 
approaching small bowel tumor patients, although nonspe-
cific, diagnostic approaches, while paying attention to the dif-
ferences in symptoms according to clinical and histological 
classification, may be important for treatment and prognosis. Journal of The Korean Society of
Coloproctology
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